Princeton Global Asset Management’s Sage Therapeutics SAGE Stock Holding History

Princeton Global Asset Management’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,000	Closed	-$9.12K	–	784
2025 Q2	$9.12K	Hold	1,000	–	–	﹤0.01%	541
2025 Q1	$7.95K	Hold	1,000	–	–	﹤0.01%	472
2024 Q4	$5.43K	Hold	1,000	–	–	﹤0.01%	536
2024 Q3	$7.22K	Hold	1,000	–	–	﹤0.01%	523
2024 Q2	$10.9K	Hold	1,000	–	–	﹤0.01%	456
2024 Q1	$18.7K	Hold	1,000	–	–	﹤0.01%	374
2023 Q4	$21.7K	Hold	1,000	–	–	0.01%	350
2023 Q3	$20.6K	Hold	1,000	–	–	0.01%	334
2023 Q2	$47K	Hold	1,000	–	–	0.01%	265
2023 Q1	$42K	Hold	1,000	–	–	0.01%	277
2022 Q4	$38K	Hold	1,000	–	–	0.01%	262
2022 Q3	$39K	Hold	1,000	–	–	0.01%	258
2022 Q2	$32K	Hold	1,000	–	–	0.01%	284
2022 Q1	$33K	Hold	1,000	–	–	0.01%	308
2021 Q4	$43K	Hold	1,000	–	–	0.01%	267
2021 Q3	$44K	Buy	+1,000	New	+$45.9K	0.01%	269

Other funds holding SAGE

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Princeton Global Asset Management's SAGE Position: Q3 2025 in Review

Princeton Global Asset Management sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 1,000 shares — an estimated $9.12K sold.

Princeton Global Asset Management first reported a position in SAGE in Q3 2021 and held it in 16 quarters. The position peaked at $47K in Q2 2023. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

Princeton Global Asset Management reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
Princeton Global Asset Management sold 1,000 Sage Therapeutics shares in Q3 2025, an estimated $9.12K.
Princeton Global Asset Management first reported a position in Sage Therapeutics in Q3 2021 and held it in 16 quarters.
Princeton Global Asset Management's Sage Therapeutics position peaked at $47K in Q2 2023.
5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on Princeton Global Asset Management's 13F filing for Q3 2025, filed 9 Oct 2025.